Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma: An Analysis of 188 Cases
Adult
Aged, 80 and over
Male
Sacrum
Spinal Neoplasms
Time Factors
Heavy Ion Radiotherapy
Radiotherapy Dosage
Walking
Middle Aged
Carbon
Tumor Burden
3. Good health
Survival Rate
03 medical and health sciences
0302 clinical medicine
Chordoma
Humans
Female
Neoplasm Recurrence, Local
Aged
Follow-Up Studies
Retrospective Studies
DOI:
10.1016/j.ijrobp.2016.02.012
Publication Date:
2016-02-08T20:32:01Z
AUTHORS (21)
ABSTRACT
To evaluate the results of carbon ion radiation therapy administered to 188 patients with unresectable primary sacral chordomas.One hundred eighty-eight patients were treated with carbon ion radiation therapy at a single institute between 1996 and 2013 and retrospectively analyzed. The median age was 66 years. The highest proximal invasion reached past S2 level in 137 patients. The median clinical target volume was 345 cm(3). One hundred six patients received 67.2 gray equivalents (GyE)/16 fractions (fr), 74 patients received 70.4 GyE/16 fr, 7 patients received 73.6 GyE/16 fr, and 1 patient received 64.0 GyE/16 fr.The median follow-up period was 62 months (range, 6.8-147.5 months). Seventy percent of patients were followed for 5 years or until death. The 5-year local control, overall survival, and disease-free survival rates were 77.2%, 81.1%, and 50.3%, respectively. Forty-one patients had a local recurrence. Sex, tumor volume, level of proximal invasion, and irradiated dose were unrelated to local control. There was grade 3 toxicity of the peripheral nerves in 6 patients and grade 4 toxicity of the skin in 2 patients. Ambulation remained in 97% of patients.Carbon ion radiation therapy was safe and effective for unresectable chordoma and provided good local control and survival while preserving ambulation.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (24)
CITATIONS (139)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....